ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
Active, not recruiting · NCT05082259 · Registry updated 2026-06-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast disorder, breast neoplasm, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma, uterine disorder | Active, not recruiting | Phase 1 | 2026-06-25 | NCT05082259 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astex Pharmaceuticals, Inc. | 12 |
| Cancer Research UK | 59 |
| Institute of Cancer Research, United Kingdom | 59 |
| Merck Sharp & Dohme LLC | 650 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cambridge University Hospitals NHS Trust | Cambridge | United Kingdom | 2 |
| The Royal Marden NHS Foundation Trust - Drug Development Unit | Sutton | United Kingdom | 1 |
| The Royal Marsden NHS Foundation Trust - Breast Unit | Sutton | United Kingdom | 1 |